While many of us were cutting out early for the holiday weekend, and to enjoy the last week of summer, New England tech and life sciences firms were cutting a surprising number of deals.

—Tufts spinoff Quanterix closed the second half of a $15 million financing round from Arch Venture Partners, Bain Capital Ventures, and Flagship Ventures. Luke talked with the Cambridge, MA-based firm’s CEO about its technology for pinpointing minute quantities of proteins in a patient’s blood that might serve as early warning signals for cancer, Alzehimer’s disease, or other ailments.

—Lexington, MA-based Mall Networks, which creates online malls that give loyalty cardholders bonus points for shopping, raised $7 million in a Series B investment led by Dace Ventures and joined by previous investors Flybridge Capital Partners, Venture Capital Fund of New England, and LBO Enterprises.

—Living Proof of Cambridge, MA, raised $7 million Series A-3 financing from Polaris Venture Partners and other investors. Though it tries to keep a low profile, the startup is using the expertise of some very high-profile scientists, investors, and executives to address the multi-billion-dollar market for beauty products.

—Cambridge, MA-based JumpTap, which provides mobile Web search and advertising technology for a variety of phones from AT&T, Alltel, Boost Mobile, U.S. Cellular, and a host of other carriers, closed a $26 million Series D financing round. The deal was led by AllianceBernstein and joined by existing investors General Catalyst Partners, Summerhill Venture Partners, Redpoint Ventures, Valhalla Partners, and WPP.

—Specialty pharmaceutical maker Indevus Pharmaceuticals (NASDAQ:INDEV) raised $105 million in a private placement of notes secured by royalties for Sanctura, the Lexington, MA-based firm’s drug for overactive bladder.

—Software-defined-radio startup Vanu of Cambridge, MA, reportedly took in $32 million a Series B venture round from Charles River Ventures, Norwest Venture Partners, and Tata Capital. The firm’s technology allows wireless operators to broadcast to use multiple standards such as GSM and CDMA.

—Dover, NH-based Salient Surgical Technologies, a maker of blood-vessel-sealing devices, pulled its planned $86.25 million initial public offering.

—Boston-based uLocate inked a deal to provide local information and mapping services for Sprint’s new nationwide WiMax network, XOHM, now under construction.

Comments | Reprints | Share:          

Indevus Pharmaceuticals (NASDAQ:INDEV), a Lexington, MA, specialty pharmaceutical firm, announced it has raised $105 million in a private placement of non-recourse notes. The company said the sale of the notes, which are secured by royalties from its overactive bladder drug Sanctura, is intended to retire existing debt due next year and fund operations into calendar 2010.

Comments | Reprints | Share: